Skip to headlines

BUSINESS

Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

CNBC BusinessFriday, September 25, 2026 at 11:00 AM

RedScroll Brief

As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.

RedScroll Signal

Impact
High
Category
Business
Market relevance
High
Why it matters
Corporate and market moves reprice risk and reveal where power and cash are concentrating. As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market. Investors will watch earnings, rates, and competitive positioning connected to Novo and Eli Lilly.
Read original source → CNBC BUSINESSEdition 2026-09-25

Desk copy

RedScroll Briefing

Extractive editorial brief — not a reprint of the original

What happened

As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.

Why it matters

Corporate and market moves reprice risk and reveal where power and cash are concentrating.

Background

CNBC Business reported on this under business. RedScroll surfaces the signal with an extractive brief — not a reprint of the original article. Read the source for full reporting.

Timeline

  1. CNBC Business published: Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

  2. Story is in today’s RedScroll edition. Follow the original source for updates.

Economic impact

Investors will watch earnings, rates, and competitive positioning connected to Novo and Eli Lilly.

More on

Related stories

Source

CNBC Business

Original reporting by CNBC Business. RedScroll provides an extractive briefing only.